New quadrivalent flu vaccine shows promise for little ones

NCT ID NCT04381689

Completed ⭐️ VACCINE ⭐️ Sponsor: Il-Yang Pharm. Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 09, 2026 · Updated 4 times

Summary

This phase 3 study tests a new quadrivalent seasonal influenza vaccine in healthy infants aged 6 months to under 3 years. The goal is to see if the vaccine triggers a strong immune response and is safe compared to an existing flu shot. About 245 children will take part, and researchers will measure antibody levels before and after vaccination.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: quadrivalent seasonal influenza vaccine
What this could lead to: If successful, this could provide a safe and effective seasonal flu vaccine option for infants and toddlers.
What could go wrong: This is a mid-stage trial with 245 participants, so results may not apply to all children. The vaccine may not work as well as expected or could cause side effects like mild fever or soreness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

influenza prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

Korea University ANSAN Hospital

Ansan-si, Gyeonnggi-do, 15355, South Korea
The Catholic University of Korea, Bucheon St. Mary's Hospital

Bucheon-si, Gyeonnggi-do, 15355, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.